Eugene D Kwon MD

PubMed

• Scrotal uptake on PSMA PET in prostate cancer: differentiating metastases from benign and physiologic findings using ultrasound correlation.
  Hiroaki Takahashi, Theodra A Potretzke, Eric C Ehman, Derek J Lomas, Lauren F Alexander
  Abdominal Radiology. 2026-09-01
• Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial.
  Nancy Wei, Ryan M Phillips, Eugene Kwon, Brad J Stish, Eric C Ehman
  BJU International. 2026-09-01
• From High Cost to High Access: The Impact of Generic Abiraterone on Medicare Part D Spending in Advanced Prostate Cancer.
  Matthew S Lee, Tae-Hee Kim, Daniel S Roberson, Vidit Sharma, Kevin M Wymer
  Urology Practice. 2026-08-04

Journal Articles

• Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer  
  Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR, Frontiers in Oncology, 1/2/2013
• Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers (Editorial)  
  Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, J Urol, 5/1/2009
• Inhibitors of the B7-CD28 constimulation in urologic malignancies  
  Thompson RH, Kwon ED, Allison JP, Future Med, 1/1/2009

Books/Book Chapters

• Renal cell carcinoma: molecular targets and clinical applications. 
  Chapter: Restoring host antitumoral immunity: how coregulatory molecules are changing the approach to the management of renal cell carcinoma. 
  Page 367 - 403Inman BA, Frigola X, Dong H, Yang JC, Kwon EDEditors: Bukowski RM, Figlin RA, Motzer RJ.Humana Press, New York, NYEdition 2nd,2009
• Current protocols in immunology. 
  Chapter: The TRAMP mouse as a model for prostate cancer. 
  Page 1 - 23Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon EDEditors: Kruisbeek AM.John Wiley & Sons, Inc.2001
• Principles and practice of the biologic therapy of cancer. 
  Chapter: CTLA-4 blockade in tumor immunotherapy. 
  Page 890 - 895Allison JP, Hurwitz AA, Elsas AV, Kwon ED, Sullivan T, Foster BA, Greenberg NMEditors: Rosenberg SA.Lippincott Williams & Wilkins, Philadelphia, PAEdition 3rd,2000

Abstracts/Posters

• Pd-1 blockade enhances radiation therapy-induced abscopal effect.
  Park SS, Dong H, Zhao W, Grams MP, Liu X, Harrington SM, Furutani KM, Krco CJ, Olivier KR, Markovic SN, Kwon ED, Int J Radiat Oncol Biol Phys, 9/1/2014
• Programmed cell death 1 ligand 1 expression and association with survival in mesothelioma.
  Mansfield AS, Peikert T, Roden A, Krco C, Harrington S, Dong H, Kwon E, J Thorac Oncol, 4/1/2014
• Characterization of immune-related adverse events (iraes) in a phase 3 trial of ipilimumab (ipi) versus placebo (pbo) in post-docetaxel mcrpc.
  Beer TM, Logothetis C, Gerritsen WR, Kwon ED, Scher HI, Bossi A, van den Eertwegh AJM, Drake CG, McHenry B, Liu D, Fizazi K, J Clin Oncol, 2/1/2014

Lectures

• CTLA-4 Blockade: From bench to bedside. 
  Lebanon, NH, 2009; Sacramento, CA, 2009 - 5/1/2009
• Immunomodulatory Therapies. 
  Chicago, IL - 9/1/2008
• Assessment of Pathologic Inclusion Criteria of Current Adjuvant Therapy Trials for Predicting Disease Recurrence Following Nephrectomy for Renal Cell Carcinoma. 
  Chicago, IL - 9/1/2008